Polypill Strategy for Heart Failure With Reduced Ejection Fraction
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health
burden in the United States, with a growing prevalence particularly among African Americans
and Hispanic Americans and individuals of low socioeconomic status (SES). Although effective
therapies exist, gaps in their uptake contribute substantially to the excess burden of heart
failure. The "polypill" is an inexpensive once daily pill containing three agents proven to
improve morbidity and mortality in heart failure and represents potential strategy for
increasing the utilization of proven HF therapies. The proposed study is a pragmatic,
single-center, randomized trial to test the feasibility and effectiveness of a polypill-based
strategy for the treatment of HFrEF in a low-income, racially diverse population.